A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease
NCT: NCT03941314 · COMPLETED
Brief Summary
The purpose of this study (superiority trial) is to compare the Supera® Peripheral Stent System with a standard nitinol self-expanding stent for treatment of femoro-popliteal arterial occlusive disease. Hypothesis: The Supera® stent is superior to a standard nitinol self-expanding stent, for treatment of femoro-popliteal artery disease in terms of (1) primary patency rate and (2) need for revascularization up to 24 months after stent insertion.
Frequently Asked Questions
What is A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease?
A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease is a clinical trial registered under NCT03941314. Current status: COMPLETED.
What is the status of NCT03941314?
The current status of NCT03941314 (A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease) is: COMPLETED.
When did A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease start?
A Superiority Trial of the SUPERA Peripheral Stent System in Patients With Femoro-popliteal Artery Disease started on 2019-06-25.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.